Paper40201702
Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.
Salahi-Niri A and 7 others. Health Sci Rep, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review. Papers, record 40201702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40201702
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35282081 | Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study. | Ann Transl Med | 2022 | https://conductscience.org/library/papers/35282081 | PubMed |
| 2 | 22081974 | Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. | BMC Cancer | 2011 | https://conductscience.org/library/papers/22081974 | PubMed |
| 3 | 23672632 | Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. | Curr Med Res Opin | 2013 | https://conductscience.org/library/papers/23672632 | PubMed |
| 4 | 20837693 | A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20837693 | PubMed |
| 5 | 26074397 | Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. | Eur J Cancer | 2015 | https://conductscience.org/library/papers/26074397 | PubMed |
| 6 | 33369635 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/33369635 | PubMed |
| 7 | 23229269 | Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. | Med Oral Patol Oral Cir Bucal | 2013 | https://conductscience.org/library/papers/23229269 | PubMed |
| 8 | 31754747 | Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. | Cancer Chemother Pharmacol | 2020 | https://conductscience.org/library/papers/31754747 | PubMed |
| 9 | 24205370 | The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. | PLoS One | 2013 | https://conductscience.org/library/papers/24205370 | PubMed |
| 10 | 16101384 | The MCM complex: its role in DNA replication and implications for cancer therapy. | Curr Cancer Drug Targets | 2005 | https://conductscience.org/library/papers/16101384 | PubMed |
| 11 | 25628920 | Prognostic significance of minichromosome maintenance proteins in breast cancer. | Am J Cancer Res | 2015 | https://conductscience.org/library/papers/25628920 | PubMed |
| 12 | 27756439 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. | Breast Cancer Res | 2016 | https://conductscience.org/library/papers/27756439 | PubMed |
| 13 | 25400769 | Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. | Int J Clin Exp Pathol | 2014 | https://conductscience.org/library/papers/25400769 | PubMed |
| 14 | 28075166 | The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. | Future Oncol | 2017 | https://conductscience.org/library/papers/28075166 | PubMed |
| 15 | 29693354 | Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas | Asian Pac J Cancer Prev | 2018 | https://conductscience.org/library/papers/29693354 | PubMed |
| 16 | 17954709 | American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17954709 | PubMed |
| 17 | 35958459 | The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer. | Am J Transl Res | 2022 | https://conductscience.org/library/papers/35958459 | PubMed |
| 18 | 21555689 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21555689 | PubMed |
| 19 | 26205655 | Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. | BMC Cancer | 2015 | https://conductscience.org/library/papers/26205655 | PubMed |
| 20 | 23917950 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23917950 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923317 | Immunohistochemical Expression of Proliferating Cell Nuclear Antigen in Invasive Breast Carcinoma: Associations With Histological Grade and Ki-67 Expression. | Cureus | 2026 | https://conductscience.org/library/papers/42923317 | PubMed |
| 42530698 | Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42530698 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PCNA | 5111 | PubTator's text mining | https://conductscience.org/library/genes/5111 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40201702
GET https://conductscience.org/api/papers/v1/40201702/references?page=2